Ocular Pain - Pipeline Review, H1 2014

Date: May 15, 2014
Pages: 51
Price:
US$ 2,000.00 US$ 1,800.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: OACB2EECFFEEN
Leaflet:

Download PDF Leaflet

Summary

Global Markets Direct’s, ‘Ocular Pain - Pipeline Review, H1 2014’, provides an overview of the Ocular Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ocular Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Pain and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Ocular Pain
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Ocular Pain and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Ocular Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Ocular Pain pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Ocular Pain
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Ocular Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential andScope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Ocular Pain Overview
Therapeutics Development
Pipeline Products for Ocular Pain - Overview
Pipeline Products for Ocular Pain - Comparative Analysis
Ocular Pain - Therapeutics under Development by Companies
Ocular Pain - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Ocular Pain - Products under Development by Companies
Ocular Pain - Companies Involved in Therapeutics Development
Sylentis S.A.
Bayer AG
InSite Vision Incorporated
Reata Pharmaceuticals, Inc.
Kala Pharmaceuticals, Inc.
Ocular Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
bromfenac sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mapracorat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SYL-1001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
loteprednol etabonate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RTA-408 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ketorolac tromethamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ocular Pain - Recent Pipeline Updates
Ocular Pain - Dormant Projects
Ocular Pain - Product Development Milestones
Featured News & Press Releases
Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery
Oct 01, 2013: Ocular Therapeutix Announces Phase 2 Study Results for Sustained Release Dexamethasone
May 24, 2013: Ista Pharma To Pay $33.5m To Resolve Criminal Liability And False Claims Act Allegations
May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery
Apr 25, 2013: Pharm-Olam Completes Phase III Ophthalmology Study Of InSite Vision's Bromsite
Apr 17, 2013: Bausch + Lomb Launches Prolensa At ASCRS Annual Meeting 2013
Apr 17, 2013: Bausch + Lomb Highlights Data On Lotemax At ASCRS Annual Meeting 2013
Apr 08, 2013: Bausch + Lomb Receives FDA Approval For Prolensa 0.07%
Mar 18, 2013: InSite Vision Reports Positive Phase III Results Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery
Jan 10, 2013: InSite Vision Completes Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Ocular Pain, H1 2014
Number of Products under Development for Ocular Pain - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Development, H1 2014
Products under Development by Companies, H1 2014
Ocular Pain - Pipeline by Sylentis S.A., H1 2014
Ocular Pain - Pipeline by Bayer AG, H1 2014
Ocular Pain - Pipeline by InSite Vision Incorporated, H1 2014
Ocular Pain - Pipeline by Reata Pharmaceuticals, Inc., H1 2014
Ocular Pain - Pipeline by Kala Pharmaceuticals, Inc., H1 2014
Assessment by Monotherapy Products, H1 2014
Number of Products by Stage and Target, H1 2014
Number of Products by Stage and Mechanism of Action, H1 2014
Number of Products by Stage and Route of Administration, H1 2014
Number of Products by Stage and Molecule Type, H1 2014
Ocular Pain Therapeutics - Recent Pipeline Updates, H1 2014
Ocular Pain - Dormant Projects, H1 2014

LIST OF FIGURES

Number of Products under Development for Ocular Pain, H1 2014
Number of Products under Development for Ocular Pain - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Assessment by Monotherapy Products, H1 2014
Number of Products by Top 10 Target, H1 2014
Number of Products by Stage and Top 10 Target, H1 2014
Number of Products by Top 10 Mechanism of Action, H1 2014
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
Number of Products by Top 10 Route of Administration, H1 2014
Number of Products by Stage and Top 10 Route of Administration, H1 2014
Number of Products by Top 10 Molecule Type, H1 2014
Number of Products by Stage and Top 10 Molecule Type, H1 2014

COMPANIES MENTIONED

Sylentis S.A.
Bayer AG
InSite Vision Incorporated
Reata Pharmaceuticals, Inc.
Kala Pharmaceuticals, Inc.
Ocular Pain - Pipeline Review, Q2 2011 US$ 450.00 May, 2011 · 32 pages
Ocular Inflammation - Pipeline Review, Q1 2011 US$ 450.00 Mar, 2011 · 45 pages
Osteoarthritis Pain - Pipeline Review, H2 2014 US$ 1,800.00 Jul, 2014 · 140 pages
Acute Pain - Pipeline Review, H2 2014 US$ 1,800.00 Jul, 2014 · 189 pages
Ocular Inflammation - Pipeline Review, Q4 2010 US$ 450.00 Nov, 2010 · 50 pages

Ask Your Question

Ocular Pain - Pipeline Review, H1 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: